Abiopharma

🔍 Abdel Raouf (Executive)

Company: EQUINIX INC (EQIX)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Acquired 364 shares of Common Stock (Direct)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 6,092.41 | transaction_form_type: 4
• Sold 0 shares of Common Stock at $1049.285 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,091.91 | transaction_form_type: 4 | Footnotes: F1
• Sold 9 shares of Common Stock at $1052.4582 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,082.91 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 12 shares of Common Stock at $1053.6426 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,070.91 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 5 shares of Common Stock at $1054.6921 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,065.91 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 15 shares of Common Stock at $1056.0056 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,050.91 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 19 shares of Common Stock at $1056.9625 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,031.91 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 9 shares of Common Stock at $1058.0457 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,022.91 | transaction_form_type: 4 | Footnotes: F1, F7
• Sold 13 shares of Common Stock at $1058.9619 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,009.91 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 15 shares of Common Stock at $1060.0029 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,994.66 | transaction_form_type: 4 | Footnotes: F1, F9
• Sold 11 shares of Common Stock at $1062.1582 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,983.66 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 13 shares of Common Stock at $1063.2345 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,970.66 | transaction_form_type: 4 | Footnotes: F1, F11
• Sold 2 shares of Common Stock at $1064.9006 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,968.66 | transaction_form_type: 4 | Footnotes: F1, F12
• Sold 3 shares of Common Stock at $1066.5465 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,965.66 | transaction_form_type: 4 | Footnotes: F1, F13
• Sold 31 shares of Common Stock at $1069.199 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,934.66 | transaction_form_type: 4 | Footnotes: F1, F14
• Sold 0 shares of Common Stock at $1070.47 per share (Direct)
  Date: 2026-06-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,934.16 | transaction_form_type: 4 | Footnotes: F1
• Sold 364 shares of Restricted Stock Unit (Derivative)
  Date: 2026-06-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 1,092.00 | transaction_form_type: 4 | Footnotes: F15, F16

Footnotes:

• F1: Shares were sold pursuant to a 10b5-1 Trading Plan in order to raise funds to pay the required withholding tax pursuant to the vesting of RSUs.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,052.095 to $1053.095, inclusive. The reporting person undertakes to provide to Equinix, Inc, any security holder of Equinix Inc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 14 to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,053.14 to $1,054.10 inclusive.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,054.33 to $1,055.315 inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,055.36 to $1,056.32 inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,056.3675 to $1,057.20 inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,057.73 to $1,058.16 inclusive.
• F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,058.79 to $1,059.04 inclusive.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,060.00 to $1,060.58 inclusive.
• F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,061.37 to $1,062.35 inclusive.
• F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,062.49 to $1,063.255 inclusive.
• F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,064.39 to $1,065.205 inclusive.
• F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,066.195 to $1,067.15 inclusive.
• F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1,069.16 to $1,069.44 inclusive.
• F15: Vesting is dependent upon continuous active service as an employee or director of the Company or a subsidiary of the Company (Service) throughout the vesting period. The Restricted Stock Units shall vest as follows: 16.67% of the RSUs vesting on June 1, 2025 and an additional 16.67% of the RSUs vesting every 6 months thereafter until fully vested.
• F16: Restricted stock unit award expires upon reporting person's termination of service.